{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T20:11:06Z","timestamp":1790885466549,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.clinthera.2025.01.017","type":"journal-article","created":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T12:08:58Z","timestamp":1740830938000},"page":"e33-e36","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Febuxostat, a Urate-Lowering Drug Bridging From Adults to Pediatrics; A Brief Report"],"prefix":"10.1016","volume":"47","author":[{"given":"Toktam","family":"Faghihi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5202-036X","authenticated-orcid":false,"given":"Farahnak","family":"Assadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2025.01.017_bib0001","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1517\/17425255.2014.904285","article-title":"Febuxostat: drug review and update","volume":"10","author":"Grewal","year":"2014","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.clinthera.2025.01.017_bib0002","first-page":"10","article-title":"Comparative effectiveness of allopurinol and febuxostat in gout management","volume":"1","author":"O'Dell","year":"2022","journal-title":"NEJM Evid"},{"key":"10.1016\/j.clinthera.2025.01.017_bib0003","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1056\/NEJMoa1710895","article-title":"CARES investigators. Cardiovascular safety of Febuxostat or allopurinol in patients with gout","volume":"378","author":"White","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2025.01.017_bib0004","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1016\/S0140-6736(20)32234-0","article-title":"FAST Study Group. Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial","volume":"396","author":"Mackenzie","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2025.01.017_bib0005","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1093\/annonc\/mdv317","article-title":"FLORENCE: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk","volume":"26","author":"Spina","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clinthera.2025.01.017_bib0006","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1007\/s10147-016-0971-3","article-title":"Efficacy and safety of febuxostat for prevention of tumor lysis syndrome in patients with malignant tumors receiving chemotherapy: a phase III, randomized, multicenter trial comparing febuxostat and allopurinol","volume":"21","author":"Tamura","year":"2016","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.clinthera.2025.01.017_bib0007","doi-asserted-by":"crossref","first-page":"21","DOI":"10.5414\/CP203466","article-title":"Comparison of long-term efficacy and renal safety of febuxostat and allopurinol in patients with chronic kidney disease","volume":"58","author":"Yang","year":"2020","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2025.01.017_bib0008","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.jbspin.2015.07.011","article-title":"Risk of cutaneous adverse events with febuxostat treatment in patients with skin reaction to allopurinol. A retrospective, hospital-based study of 101 patients with consecutive allopurinol and febuxostat treatment","volume":"83","author":"Bardin","year":"2016","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.clinthera.2025.01.017_bib0009","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3810\/pgm.2014.03.2741","article-title":"Achieving serum urate goal: a comparative effectiveness study between allopurinol and febuxostat","volume":"126","author":"Hatoum","year":"2014","journal-title":"Postgrad Med"},{"key":"10.1016\/j.clinthera.2025.01.017_bib0010","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/j.mayocp.2019.03.001","article-title":"Comparing cardiovascular safety of Febuxostat and allopurinol in the real world: a population-based cohort study","volume":"94","author":"Su","year":"2019","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.clinthera.2025.01.017_bib0011","doi-asserted-by":"crossref","DOI":"10.1177\/03000605211062770","article-title":"Multicenter randomized trial investigators. Comparison between febuxostat and allopurinol uric acid-lowering therapy in patients with chronic heart failure and hyperuricemia: a multicenter randomized controlled trial","volume":"49","author":"Suzuki","year":"2021","journal-title":"J Int Med Res"},{"key":"10.1016\/j.clinthera.2025.01.017_bib0012","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s00296-014-3189-6","article-title":"Safety of allopurinol compared with other urate-lowering drugs in patients with gout: a systematic review and meta-analysis","volume":"35","author":"Castrejon","year":"2015","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.clinthera.2025.01.017_bib0013","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1093\/eurheartj\/ehz119","article-title":"Febuxostat for cerebral and cardiorenovascular events PrEvEntion study","volume":"40","author":"Kojima","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clinthera.2025.01.017_bib0014","first-page":"525","article-title":"Febuxostat administration for the prevention of tumor lysis syndrome: a meta-analysis","volume":"44","author":"Bellos","year":"2019","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.clinthera.2025.01.017_bib0015","doi-asserted-by":"crossref","first-page":"731","DOI":"10.2147\/TCRM.S424598","article-title":"Hepatic safety of febuxostat and allopurinol for gout patients: a systematic review of randomized controlled trial","volume":"19","author":"Dewi","year":"2023","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.clinthera.2025.01.017_bib0016","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.numecd.2019.06.016","article-title":"The net clinical benefits of febuxostat versus allopurinol in patients with gout or asymptomatic hyperuricemia \u2013 a systematic review and meta-analysis","volume":"29","author":"Liu","year":"2019","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1016\/j.clinthera.2025.01.017_bib0017","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/BOR.0000000000000573","article-title":"The role of febuxostat in gout","volume":"31","author":"Bardin","year":"2019","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.clinthera.2025.01.017_bib0018","doi-asserted-by":"crossref","first-page":"389","DOI":"10.2146\/ajhp100394","article-title":"Febuxostat for treatment of chronic gout","volume":"68","author":"Gray","year":"2011","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.clinthera.2025.01.017_bib0019","series-title":"StatPearls","article-title":"Febuxostat","author":"Gerriets","year":"2024"},{"key":"10.1016\/j.clinthera.2025.01.017_bib0020","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1002\/hep.28403","article-title":"Drug-induced liver injury network (DILIN). Febuxostat-induced acute liver injury","volume":"63","author":"Bohm","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.clinthera.2025.01.017_bib0021","first-page":"e11697","article-title":"Gout in pregnancy: a rare phenomenon","volume":"12","author":"Pierre","year":"2020","journal-title":"Cureus"},{"key":"10.1016\/j.clinthera.2025.01.017_bib0022","series-title":"Database (LactMed\u00ae)","year":"2023"},{"key":"10.1016\/j.clinthera.2025.01.017_bib0023","doi-asserted-by":"crossref","first-page":"2019-8-2","DOI":"10.7573\/dic.2019-8-2","article-title":"Tumor lysis syndrome in childhood malignancies","volume":"9","author":"Cheung","year":"2020","journal-title":"Drugs Context"},{"key":"10.1016\/j.clinthera.2025.01.017_bib0024","first-page":"359","article-title":"Efficacy and safety of allopurinol on chronic kidney disease progression: a systematic review and meta-analysis","volume":"29","author":"Sharbaf","year":"2024","journal-title":"J Pediatr Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2025.01.017_bib0025","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1007\/s00467-018-3943-1","article-title":"Effect of allopurinol on the glomerular filtration rate of children with chronic kidney disease","volume":"33","author":"Ghane Sharbaf","year":"2018","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.clinthera.2025.01.017_bib0026","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s40620-013-0009-0","article-title":"Allopurinol enhances the blood pressure lowering effect of enalapril in children with hyperuricemic essential hypertension","volume":"27","author":"Assadi","year":"2014","journal-title":"J Nephrol"},{"key":"10.1016\/j.clinthera.2025.01.017_bib0027","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1093\/mr\/roae056","article-title":"Efficacy and safety of febuxostat in Japanese pediatric patients with hyperuricaemia including gout: phase 2, single-arm, open-label, multicentre studies","volume":"35","author":"Ito","year":"2024","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.clinthera.2025.01.017_bib0028","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1136\/annrheumdis-2021-221762","article-title":"Clinical characteristics of juvenile gout and treatment response to febuxostat","volume":"81","author":"Zheng","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clinthera.2025.01.017_bib0029","first-page":"5845","article-title":"Febuxostat as a prophylaxis for tumor lysis syndrome in children with hematological malignancies","volume":"37","author":"Kishimoto","year":"2017","journal-title":"Anticancer Res"},{"key":"10.1016\/j.clinthera.2025.01.017_bib0030","doi-asserted-by":"crossref","first-page":"4868","DOI":"10.1182\/blood.V126.23.4868.4868","article-title":"Febuxostat pharmacokinetic\/pharmacodynamics bridging from adults to pediatrics for effective prophylaxis of tumor lysis syndrome: from Florence to Floret study","volume":"126","author":"Spina","year":"2015","journal-title":"Blood"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291825000311?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291825000311?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T12:35:06Z","timestamp":1744202106000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291825000311"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S0149291825000311"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2025.01.017","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Febuxostat, a Urate-Lowering Drug Bridging From Adults to Pediatrics; A Brief Report","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2025.01.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}